Patents by Inventor Gun-Hwa Kim

Gun-Hwa Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220402890
    Abstract: The present invention relates to a novel quinoline compound and a use thereof and to a novel quinoline compound exhibiting CYP4A inhibition activity and a use thereof for preventing, alleviating, treating a metabolic disease. The compound disclosed in the present invention has a remarkable effect of inhibiting CYP4A and exhibits the activities of promoting the absorption of glucose into hepatocytes, inhibiting fat accumulation in hepatocytes, suppressing endoplasmic reticulum-induced reactive oxygen species, and treating steatohepatitis, and thus can be very advantageously used for developing therapeutics for metabolic diseases such as diabetes mellitus and fatty liver.
    Type: Application
    Filed: November 11, 2020
    Publication date: December 22, 2022
    Inventors: Ho Sang Moon, Bosung Ku, Jungwon Kim, Do Hyeong Na, Gun Hwa Kim, Sin Hyoung Hong, Min Ji Lee, Ji Hoon Lee
  • Publication number: 20220218726
    Abstract: The present invention relates to a composition comprising a CYP4A-inhibiting compound as an active ingredient for preventing or treating metabolic diseases, more specifically to a composition comprising the compound expressed by chemical formula 1 of the present invention or pharmaceutically acceptable salt thereof as an active ingredient for preventing, ameliorating or treating metabolic diseases.
    Type: Application
    Filed: December 19, 2019
    Publication date: July 14, 2022
    Inventors: Gun Hwa Kim, Min Ji Lee, Koon Soon Kim, Hyo Kyun Chung, Ji Hoon Lee, Se Jin Jung, Da Rong Kim
  • Patent number: 10266898
    Abstract: The present invention relates to a recurring glioblastoma multiforme marker miRNA for diagnosing recurring glioblastoma multiforme, and more specifically, to a composition for screening the miRNA marker, which is specific to the recurring glioblastoma multiforme and comprises an agent for detecting the presence of the marker, a kit, and to a method for diagnosing the recurring glioblastoma multiforme using same. The method for diagnosing the recurring glioblastoma multiforme by using the recurring glioblastoma multiforme marker miRNA, according to the present invention, provides glioblastoma markers, which can diagnose the occurrence of the recurring glioblastoma multiforme, thereby providing useful material for managing treatment and prognosis of the recurring glioblastoma multiforme. In addition, the diagnosis markers for the recurring glioblastoma multiforme can be used for development and research of an anticancer agent specific to the recurring glioblastoma multiforme.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: April 23, 2019
    Assignee: KOREA BASIC SCIENCE INSTITUTE
    Inventors: Gun-Hwa Kim, Giwon Kim, Soohyun Kim, Seung II Kim, Edmond Changkyun Park
  • Patent number: 10166223
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes or fatty liver comprising a CYP4A (cytochrome P450A) inhibitor as an active ingredient. The compound of the present invention has activities of promoting glucose uptake into hepatocytes, inhibiting fat accumulation in liver cells, and inhibiting reactive oxygen production in mitochondria, and thus can be very usefully used for the development of a therapeutic agent for diabetes or fatty liver.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: January 1, 2019
    Assignee: KOREA BASIC SCIENCE INSTITUTE
    Inventors: Gun Hwa Kim, Joo Hyun Park, Min Ji Lee
  • Publication number: 20180333404
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetes or fatty liver comprising a CYP4A (cytochrome P450A) inhibitor as an active ingredient. The compound of the present invention has activities of promoting glucose uptake into hepatocytes, inhibiting fat accumulation in liver cells, and inhibiting reactive oxygen production in mitochondria, and thus can be very usefully used for the development of a therapeutic agent for diabetes or fatty liver.
    Type: Application
    Filed: May 18, 2018
    Publication date: November 22, 2018
    Inventors: Gun Hwa Kim, Joo Hyun Park, Min Ji Lee
  • Patent number: 9295667
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A (cytochrome P450A) inhibitor as an active ingredient. According to the present invention, the CYP4A inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver.
    Type: Grant
    Filed: February 11, 2014
    Date of Patent: March 29, 2016
    Assignee: Korea Basic Science Institute
    Inventors: Gun-Hwa Kim, Soohyun Kim, Jong-Soon Choi, Seung Il Kim, Edmond Changkyun Park
  • Publication number: 20150232946
    Abstract: The present invention relates to a recurring glioblastoma multiforme marker miRNA for diagnosing recurring glioblastoma multiforme, and more specifically, to a composition for screening the miRNA marker, which is specific to the recurring glioblastoma multiforme and comprises an agent for detecting the presence of the marker, a kit, and to a method for diagnosing the recurring glioblastoma multiforme using same. The method for diagnosing the recurring glioblastoma multiforme by using the recurring glioblastoma multiforme marker miRNA, according to the present invention, provides glioblastoma markers, which can diagnose the occurrence of the recurring glioblastoma multiforme, thereby providing useful material for managing treatment and prognosis of the recurring glioblastoma multiforme. In addition, the diagnosis markers for the recurring glioblastoma multiforme can be used for development and research of an anticancer agent specific to the recurring glioblastoma multiforme.
    Type: Application
    Filed: January 20, 2015
    Publication date: August 20, 2015
    Inventors: Gun-Hwa Kim, Giwon Kim, Soohyun Kim, Seung II Kim, Edmond Changkyun Park
  • Publication number: 20140275198
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver, and more specifically relates to a pharmaceutical composition for preventing or treating diabetes or fatty liver containing a CYP4A (cytochrome P450A) inhibitor as an active ingredient. According to the present invention, the CYP4A inhibitor suppresses endoplasmic reticulum stress, reduces the blood insulin concentration and suppresses apoptosis of liver cells, and hence exhibits effects in preventing or treating diabetes or fatty liver.
    Type: Application
    Filed: February 11, 2014
    Publication date: September 18, 2014
    Applicant: Korea Basic Science Institute
    Inventors: Gun-Hwa Kim, Soohyun Kim, Jong-Soon Choi, Seung II Kim, Edmond Changkyun Park